This document details the acquisition of Prexton Therapeutics BV by H. Lundbeck A/S in a deal valued at up to €905 million. Under the agreement, Lundbeck will pay €100 million upfront and up to €805 million in development, regulatory, and sales milestones.

Through this acquisition, Lundbeck secures global rights to foliglurax, a first-in-class small molecule targeting the metabotropic glutamate receptor 4 (mGluR4). Foliglurax entered Phase II clinical trials in 2017, aiming to reduce OFF-time and levodopa-induced dyskinesia in patients with Parkinson’s disease. By activating compensatory neuronal pathways, this innovative therapy seeks to improve both motor and non-motor symptoms, addressing the unmet medical needs that remain despite current dopaminergic treatments.

The document also outlines the scientific foundation of foliglurax, the global burden of Parkinson’s disease, and the strategic role of investors and partners in supporting Prexton’s pioneering work. The acquisition underscores Lundbeck’s commitment to developing novel therapies for central nervous system disorders.